• David Becker

    One of the two groups Janet Yellen mentioned as being “stretched” include biotechs stocks. The share prices experienced robust returns in 2013 but since March of 2014 have had difficulty sustaining any substantial rally. Biotech’s have underachieved this since the spring. The Biotech iShares (IBB) is trading well below their February high. Their relative strength

  • Business » OncoMed Roars on Partnership News
    December 4, 2013, 07:19 GMT

    The biotechnology space has been a hot bed for investment over the last year as investors searched for undervalued growth in a market at all time highs. Many familiar names including Gilead, Celegene (NASDAQ:CELG) , and Amgen (NASDAQ:AMGN) have roared higher on strong pipeline data and acquisition. However, in recent weeks, some of the smaller, higher

  • Business » Amgen’s cancer deal
    August 27, 2013, 08:44 GMT

    Amgen (NASDAQ:AMGN) made headlines on Monday morning when it was announced the long awaited deal with Onyx Pharmaceuticals finally closed. An approaching patent cliff has pushed the company to look for large deals within the pharma space. Onyx has agreed to sell for roughly $10.4 billion in cash, making the deal one of the largest